ESMO 2023 – some Tropion fears allayed
However, lack of meaningful efficacy in Tropion-Lung01 suggests that datopotamab deruxtecan might be restricted to a histology-defined NSCLC subgroup.
What’s that, a win for CD47?
ALX Oncology claims the first ever success for a CD47 inhibitor in a global randomised solid tumour study.
ESMO 2023 preview – J&J pulls a Mariposa rabbit out of the hat
And there won’t be a long to wait for the full data, with revelation that Mariposa features among numerous practice-changing late-breakers at ESMO.
Astra works to avoid a datopotamab double dip
As Tropion-Breast01 is toplined positive Astra ensures the markets know that overall survival isn’t a washout.
No end in sight for antibody-drug conjugate enthusiasm
One first-in-human study and two deals in a single day sees companies blaze the ADC trail.
World Lung 2023 preview – Astra’s Tagrisso showdown
Flaura2 takes centre stage, while Trodelvy and dato square off in PD-1 combo trials.
